advertisement
Abstract #3612 Published in IGR 4-2
Clinical research on 0.2% alphagan and 0.5% timolol in primary open-angle glaucoma and ocular hypertension
Zhong L; Li MChinese Ophthalmic Research 2002; 20: 153-156
OBJECTIVE: To investigate the safety and efficacy of 0.2% alphagan in treating primary open-angle glaucoma and ocular hypertension. METHODS: There were 43 patients with primary open-angle glaucoma or ocular hypertension. The patients were divided randomly into two groups: an alphagan group and a timolol group. The alphagan group received 0.2% alphagan drops twice a day and the timolol group 0.5% timolol drops twice a day. Intraocular pressure (IOP), heartbeat, and blood pressure (systolic and diastolic pressures) of the patients were evaluated before treatment and at one, two, four, six, and eight weeks after treatment. RESULTS: The average values of IOP after one, two, four, six, and eight weeks of treatment were significantly different compared to that of baseline IOP before treatment in both the alphagan and the timolol groups (p < 0.01). The ocular hypotensive efficacy in the two groups was confirmed. There were less topical and systematic side-effects in the alphagan group, but heartbeat decreased in the timolol group. Blood pressure was not influenced in either group. CONCLUSIONS: 0.2% Alphagan may become the drug of choice in antiglaucomatous drops, especially in patients with cardiovascular diseases. LA: Chinese
Dr. L. Zhong, Department of Ophthalmology, First Hospital, Beijing University, Beijing 100034, China
Classification:
11.3.3 Apraclonidine, brimonidine (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
